Literature DB >> 26367129

Protocol registration and selective outcome reporting in recent psychiatry trials: new antidepressants and cognitive behavioural therapies.

K Shinohara1, A Tajika1, H Imai1, N Takeshima1, Y Hayasaka1, T A Furukawa1.   

Abstract

OBJECTIVE: The selective reporting of favorable outcomes has a serious influence on our evidence base. However, this problem has not yet been systematically investigated in the field of psychiatry. Our study aimed to evaluate registration and outcome reporting in randomized controlled trials (RCTs) of standard treatments for depression: cognitive behavioural therapy (CBT) or new-generation antidepressants (ADs).
METHOD: We searched for reports of RCTs examining the efficacy of CBT or AD for depression that were published between 2011 and 2013. We then compared their primary outcomes in the trial registries and those in publications.
RESULTS: We identified 170 trials. Among them, 92 trials (54.1%) were registered, 43 trials (25.3%) were properly registered, and only 32 (18.8%) trials were both properly registered and reported (the primary outcomes as recorded in the registries were reported in publications). There was no statistically significant difference in the proportions of properly registered and reported trials for CBT or AD (relative risk: 0.51, 95% CI: 0.25-1.03). High impact factor journals, commercial funding, publication of protocol, and relatively large sample size were significant predictors of proper registration and reporting.
CONCLUSION: The prevalence of proper registration and reporting is still very low in depression trials.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antidepressive agents; clinical trials; cognitive therapy; treatment outcome

Mesh:

Substances:

Year:  2015        PMID: 26367129     DOI: 10.1111/acps.12502

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

1.  Registry versus publication: discrepancy of primary outcomes and possible outcome reporting bias in child and adolescent mental health.

Authors:  Nikolina Vrljičak Davidović; Luka Komić; Ivana Mešin; Mihaela Kotarac; Donald Okmažić; Tomislav Franić
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-18       Impact factor: 4.785

2.  Why prudence is needed when interpreting articles reporting clinical trial results in mental health.

Authors:  Rafael Dal-Ré; Julio Bobes; Pim Cuijpers
Journal:  Trials       Date:  2017-03-28       Impact factor: 2.279

3.  Registration of published randomized trials: a systematic review and meta-analysis.

Authors:  Ludovic Trinquart; Adam G Dunn; Florence T Bourgeois
Journal:  BMC Med       Date:  2018-10-16       Impact factor: 8.775

4.  Influence of overstated abstract conclusions on clinicians: a web-based randomised controlled trial.

Authors:  Kiyomi Shinohara; Takuya Aoki; Ryuhei So; Yasushi Tsujimoto; Aya M Suganuma; Morito Kise; Toshi A Furukawa
Journal:  BMJ Open       Date:  2017-12-14       Impact factor: 2.692

5.  Overstatements in abstract conclusions claiming effectiveness of interventions in psychiatry: A meta-epidemiological investigation.

Authors:  Kiyomi Shinohara; Aya M Suganuma; Hissei Imai; Nozomi Takeshima; Yu Hayasaka; Toshi A Furukawa
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

6.  Publication and non-publication of clinical trials in PTSD: an overview.

Authors:  Sharain Suliman; Leigh van den Heuvel; Alexandra Suryapranata; Jonathan I Bisson; Soraya Seedat
Journal:  Res Integr Peer Rev       Date:  2019-07-25

7.  Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials.

Authors:  Erick H Turner; Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Ymkje Anna de Vries
Journal:  PLoS Med       Date:  2022-01-19       Impact factor: 11.069

8.  Reporting bias in clinical trials: Progress toward transparency and next steps.

Authors:  Mayookha Mitra-Majumdar; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2022-01-19       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.